Portuguese pharmaceutical company Bial announced on Tuesday that the Phase 2b (activate) clinical trial evaluating drug BIA 28-6156 in patients with Parkinson’s disease, which was the most [...]
The Portuguese pharmaceutical company Bial, which last year celebrated its centenary, is a household name in Portugal and well known in the field of specialised epilepsy and Parkinson’s treatment [...]
